Your Health, We Care
Release date: 2026-01-13 16:59:35 Article From: Lucius Laos Recommended: 118
Capivasertib in combination with Faslodex is indicated for the treatment of adult patients with a specific type of hormone receptor-positive (hormone-dependent, e.g., estrogen-dependent) advanced breast cancer that has spread to adjacent tissues or other parts of the body, and whose disease has progressed during or after certain other therapies.
Capivasertib is also used in combination with another medication plus Faslodex for the treatment of a specific type of hormone receptor-positive advanced breast cancer that has metastasized to other parts of the body, in premenopausal (menopause; cessation of menstruation), perimenopausal and postmenopausal female patients. Capivasertib belongs to the class of medications known as kinase inhibitors. It works by blocking the signal transmission of an abnormal protein that instructs cancer cells to proliferate, thereby helping to slow down or prevent the spread of cancer cells.
Do not consume grapefruit or drink grapefruit juice while taking this medication.
Take the missed dose as soon as you remember it. However, if more than 4 hours have passed since the scheduled time, skip the missed dose and continue with your regular dosing schedule. Do not double the dose to make up for a missed one.
1. Capivasertib may cause side effects. Tell your doctor if any of the following symptoms are severe or do not go away: nausea, vomiting, mouth ulcers, fatigue, decreased appetite, headache.
2. Some side effects can be serious. Stop taking the medication immediately and call your doctor or seek emergency medical attention if you experience any of the following symptoms or those listed in the Special Precautions section:
3. Skin rash; blistering, peeling, dryness or redness of the skin; blisters on the lips, eyes or mouth; fever; flu-like symptoms
4. Diarrhea (loose, watery stools or increased frequency of bowel movements); stomach cramps
5. Dry mouth, weakness, decreased urine output, swelling of the legs or ankles
6. Frequent urination, painful urination or urgent need to urinate
7. Capivasertib may cause other side effects. Call your doctor if you have any unusual problems while taking this medication.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：2622025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：4832024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：2672025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：2772025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：2582025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：3032025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：2652025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended：2442025-27-11
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
